Form 4: Glaukos Corp Director Kliman Sells Shares and Exercises Options

Director Gilbert H. Kliman sold Glaukos Corp shares and exercised stock options, according to a recent SEC Form 4 filing.

Summary

• Director Gilbert H. Kliman of Glaukos Corp reported transactions involving the company's stock.
• On March 6, 2024, Kliman sold 3,145 shares of common stock at a weighted average price of $86.01 and 5,202 shares at a weighted average price of $84.93.
• On March 7, 2024, Kliman exercised a stock option for 5,000 shares at a price of $32 and sold those shares at a weighted average price of $88.25.
• Following these transactions, Kliman directly owns 30,620 shares and indirectly owns 0 shares through InterWest Venture Management Company.
• The filing also notes that Kliman has sole voting and investment control over shares held by InterWest Venture Management Company.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. It doesn't inherently indicate positive or negative outlook for the company.

Industry Context

This filing reflects the trading activity of a company insider and is a routine part of regulatory compliance. It provides transparency into the actions of company leadership but doesn't necessarily indicate a broader trend within the ophthalmic medical device industry.

Comparison to Industry Standards

• Insider trading activity is common across publicly listed companies, and the reported transactions are typical for executives managing their stock holdings and option grants.
• Similar filings can be observed for executives at companies like Alcon, Johnson & Johnson Vision, and Bausch + Lomb, reflecting the personal financial decisions of these individuals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates